No Data
Ruikang Pharmaceutical: Report for the first quarter of 2025
Realcan Pharmaceutical Group: 2024 Annual Report
Realcan Pharmaceutical Group: Summary of the 2024 Annual Report
Realcan Pharmaceutical Group (002589.SZ): has repurchased a total of 0.95% of its shares.
On April 7, Guolonghui reported that Realcan Pharmaceutical Group (002589.SZ) announced that as of March 31, 2025, the company repurchased 14.29114 million shares through a dedicated securities account for share repurchase via centralized bidding, accounting for 0.95% of the company's current total equity, with a highest Fill Price of 3.08 yuan/share, a lowest Fill Price of 2.93 yuan/share, and a total transaction amount of 42.857768 million yuan (excluding transaction fees).
Realcan Pharmaceutical Releases Correction on Auditor's Penalties; Shares Slump 10%
Realcan Pharmaceutical Group (002589.SZ): A total of 0.7% of shares have been repurchased.
On March 4, Gelonghui reported that Realcan Pharmaceutical Group (002589.SZ) announced that as of February 28, 2025, the company repurchased 10.51155 million shares through a dedicated securities account for share buybacks via centralized bidding, accounting for 0.70% of the company's total share capital. The highest Fill Price was 3.08 yuan/share, the lowest Fill Price was 2.93 yuan/share, and the total amount of the transaction was 31.653535 million yuan (excluding transaction fees). This share repurchase complies with the company's established share buyback plan and relevant laws and regulations.
Benign Growth For Realcan Pharmaceutical Group Co., Ltd. (SZSE:002589) Underpins Stock's 30% Plummet
